MapLight Therapeutics, Inc. (MPLT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.22-7.30%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · MPLT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -77.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
MPLT — private placement
Dated 2026-08-13
Entry Into A Material Definitive Agreement. On August 13, 2026, MapLight Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 9,197,887 shares (the “ Shares ”) of the Company’s voting common stock, par value $0.0001 (“ Common Stock ”) per s…
Why it matters: FDA feedback will shape the next test of ML-007C-MA in schizophrenia. A clear path would build on ZEPHYR's positive Phase 2 result.
Supportive ifThe FDA meeting supports the planned Phase 3 ZEPHYR-2 design, and the company starts the trial without a major delay.
Worry ifThe FDA asks for more studies or major trial changes, or ZEPHYR-2 does not start as planned.
Why it matters: VISTA is testing the same drug in Alzheimer’s disease psychosis. Its results are a key test beyond schizophrenia.
Watch forThe company reports VISTA enrollment remains on track, with topline results still set for the second half of 2027.
Also watch forThe company reports a VISTA enrollment delay. Or it moves topline results beyond the second half of 2027.
Why it matters: The company says its cash and new financing can fund ML-007C-MA through 2028. Higher costs or a shorter runway could pressure trial plans.
Worry ifAt the December 3 earnings report, MapLight keeps its cash runway estimate through 2028.
Less concerning ifMapLight cuts its runway estimate to before 2028 or reports a financing need to keep planned trials moving.
Why it matters: IRIS missed its main goal, but teens with more severe irritability improved. FDA feedback will show whether that result supports another study.
Watch forThe FDA meeting leads to a clear next-step plan for ML-004, such as a new trial focused on irritability.
Also watch forThe company says it will not fund another ML-004 trial or gives no next-step plan after FDA talks.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$283 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $783 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,314 loss on $10,000 · 83.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Second-quarter research costs nearly doubled from a year earlier. Further cost growth could make the stated cash plan harder to meet.
Worry ifResearch and development costs top $53.4 million again this quarter. The company also lowers its runway estimate.
Less concerning ifQuarterly research and development costs fall below $53.4 million. The runway estimate stays through 2028.